Parameter
| Biomarker | MMP-9/TIMP-1 ratio | Full name | Matrix metalloproteinase-9/Tissue inhibitor of metalloproteinase-1 ratio | Molecular Type | Protein (matrix metalloproteinases/inhibitor) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Fibrosis monitoring and prognosis | ||
| Disease | Acute pancreatitis (AP) | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Serum (ELISA, Immunoblotting) | ||
| Pathobiological Mechanisms | MMP-9 is involved in pancreatic tissue remodeling, and TIMP-1 inhibits its activity. The increased ratio of MMP-9 to TIMP-1 indicates an increased risk of pancreatic fibrosis progression | ||||
| Clinical Availability Status | Clinical research phase: Ratio abnormalities have been identified in patients with AP and used to assess the risk of fibrosis | ||||
| Notes and Dynamics | It can predict the risk of AP transformation to chronic pancreatitis and provide a basis for early intervention. At present, it is being verified by expanding the sample size | ||||